August 2021 Top Biopharma Deal: RemeGen – Seagen HER2-targeted ADC, Disitamab Vedotin for Solid Tumors
Highlighted Deal Financial Comps
Total Deal Value:
Cost & Profit Split:
- RemeGen granted Seagen exclusive, worldwide rights, excluding parts of Asia, to co-develop and commercialize HER2-targeted ADC, disitamab vedotin for the treatment of several solid tumor types including urothelial, gastric, and breast cancer.
- RemeGen will retain development and commercialization rights in Asia excluding Japan and Singapore and will be responsible for all submissions specific to its territory.
- Seagen will lead global clinical development and RemeGen will fund and operate clinical trials attributable to its territory.
- RemeGen will receive $200M up front and is eligible for up to $2.4B in development, regulatory, and commercialization milestones, plus undisclosed tiered, high single-digit to mid-teens royalties.
Congrats to RemGen and Seagen for landing the DealForma August 2021 Top Biopharma Deal of the Month. The Deal of the Month for July 2021 was Arvinas and Pfizer’s PROTAC deal with $1B up front for ARV-471. Read about it here.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.
We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
Drug Sales Figures
All of this by stage, disease indication, modality, target...
More Research by DealForma
An increase in down rounds in 2023 indicates a reassessment of valuations in VC. Challenges are expected to persist in the sector through the H1 of 2024, grappling with repercussions from previous excesses and a challenging fundraising environment. The initiation of a...
This year, DealForma's CEO Chris Dokomajilar joined Inpart for the webinar to review life sciences dealmaking for 2024. Inpart has also put together an eBook which talks about the trends, analysis and forecasts for 2024. It seems that biopharma is ready to bounce back...